Medicamen Biotech share news, announcements and annual reports
NSE: MEDICAMEQBSE: 531146Pharmaceuticals & BiotechnologySmall Cap
Medicamen Biotech Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1995 on BSE, Oct 2021 on NSE
Last close ₹256.20down ₹10.75 (4.03%)BSE ₹255.50
Share price at the NSE close on 30 Oct 2026. Previous close ₹266.95.
30 Oct: open ₹269.75, high ₹274.00, low ₹255.00
52-week range of traded prices to 30 Oct 2026
₹212.40Low, 29 Jun 2026₹447.65High, 25 Nov 2025
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹360 Cr1,991st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.31
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.39%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.17
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 12,960
Medicamen Biotech disputes and clarifications
11 filed, newest first.
Dec 2024
6 Dec · Legal
Significant movement in price has been observed in Medicamen Biotech Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Sep 2024
26 Sep · Legal
The exchange asked on 25 Sep 2024
Jul 2024
Jun 2024
21 Jun · Legal
Exchange has sought clarification from Medicamen Biotech Limited for the quarter ended 31-Mar-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Oct 2023
31 Oct · Legal
The exchange asked on 30 Oct 2023
Sep 2022
7 Sep · Legal
Exchange has sought clarification from Medicamen Biotech Limited with respect to Financial Results dated 10-Aug-2022 for the period Jun, 2022On the basis of aforesaid disclosure, the Listed entity is required to clarify the following:1.Standalone & Consolidated : Audit Report or Limited Review - Same UDIN The response of the company is awaited
Aug 2022
30 Aug · Legal
Exchange has sought clarification from Medicamen Biotech Limited with respect to announcement dated 26-Aug-2022 informing about Extra Ordinary Meeting.On the basis of aforesaid announcement, the Company is required to provide/clarify the following: 1. Brief details of items deliberated and results thereof; The response of the company is awaited.
Apr 2022
12 Apr · Legal
The exchange asked on 6 Apr 2022